Estrogen receptor-positive breast carcinomas in younger women are different from those of older women: A pathological and immunohistochemical study

Breast

Volumn 19, Issue 2, 2010, Pages 137-141

  Bacchi, L M ^a   Corpa, M ^b   Santos, P P ^a   Bacchi, C E ^b   Carvalho, F M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Consultoria em Patologia ^*  (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; PROTEIN P63; STEM CELL FACTOR RECEPTOR; VIMENTIN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MORPHOLOGY; PRIORITY JOURNAL; TISSUE MICROARRAY;

EID: 77951207155     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2010.01.002     Document Type: Article

References (32)

1. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
2. Acharya C.R., Hsu D.S., Anders C.K., et al. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA 2008, 299:1574-1587.
3. Sorlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer 2004, 40:2667-2675.
4. Goldhirsch A., Wood W.C., Gelber R.D., et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007, 18:1133-1144.
5. Anders C.K., Hsu D.S., Broadwater G., et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 2008, 26:3324-3330.
6. El Saghir N.S., Seoud M., Khalil M.K., et al. Effects of young age at presentation on survival in breast cancer. BMC Cancer 2006, 6:194.
7. Nielsen T.O., Hsu F.D., Jensen K., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004, 10:5367-5374.
8. Bhargava R., Striebel J., Beriwal S., et al. Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int J Clin Exp Pathol 2009, 2:444-455.
9. Goldstein N.S., Decker D., Severson D., et al. Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer 2007, 110:1687-1696.
10. Cheang M.C., Chia S.K., Voduc D., et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009, 101:736-750.
11. Hugh J., Hanson J., Cheang M.C., et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009, 27:1168-1176.
12. Golshan M., Miron A., Nixon A.J., et al. The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy. Am J Surg 2006, 192:58-62.
13. Lakhani S.R., Reis-Filho J.S., Fulford L., et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res. 2005, 11:5175-5180.
14. Graeser M., Bosse K., Brosig M., et al. Association of hormone receptor status with grading, age of onset, and tumor size in BRCA1-associated breast cancer. Virchows Arch. 2009, 454:519-524.
15. Bori R., Cserni G. Basal phenotype in breast carcinoma occurring in women aged 35 or younger. Pathol Oncol Res. 2009, 15:41-45.
16. Bacchi L.C.M., Bacchi C.E., Carvalho F.M. Pathological and molecular characterization of breast carcinomas of young women. Rev Bras Mastol 2009, 19:42-46.
17. Wolff A.C., Hammond M.E., Schwartz J.N., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145.
18. Phillips T., Murray G., Wakamiya K., et al. Development of standard estrogen and progesterone receptor immunohistochemical assays for selection of patients for antihormonal therapy. Appl Immunohistochem Mol Morphol 2007, 15:325-331.
19. Tamimi R.M., Baer H.J., Marotti J., et al. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res. 2008, 10:R67.
20. Carey L.A., Perou C.M., Livasy C.A., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2502.
21. Munoz M., Fernandez-Acenero M.J., Martin S., Schneider J. Prognostic significance of molecular classification of breast invasive ductal carcinoma. Arch Gynecol Obstet 2009, 280:43-48.
22. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
23. Diaz L.K., Sneige N. Estrogen receptor analysis for breast cancer: current issues and keys to increasing testing accuracy. Adv Anat Pathol 2005, 12:10-19.
24. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874.
25. Sorlie T., Wang Y., Xiao C., et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 2006, 7:127.
26. Durbecq V., Ameye L., Veys I., et al. A significant proportion of elderly patients develop hormone-dependant 'luminal-B' tumours associated with aggressive characteristics. Crit Rev Oncol Hematol 2008, 67:80-92.
27. Loi S., Haibe-Kains B., Desmedt C., et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007, 25:1239-1246.
28. Ross J.S., Hatzis C., Symmans W.F., et al. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 2008, 13:477-493.
29. Badve S., Nakshatri H. Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. J Clin Pathol 2009, 62:6-12.
30. Vaziri S.A., Krumroy L.M., Elson P., et al. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. Clin Cancer Res. 2001, 7:1937-1945.
31. Charpin C., Giusiano S., Charfi S., et al. Quantitative immunohistochemical expression of c Kit in breast carcinomas is predictive of patients' outcome. Br J Cancer 2009, 101:48-54.
32. Azoulay S., Lae M., Freneaux P., et al. KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. Mod Pathol 2005, 18:1623-1631.